Wall St. slips on tech results, chances of Fed hike

Margin Pressures Could Weigh on CVS Health (CVS) Shares; Oppenheimer Cuts Price Target to $115

Oppenheimer maintained an Outperform rating on CVS Health (NYSE: CVS), and cut the price target to $115.00 (from $122.00), following the company's 3Q earnings results. CVS reported 3Q revenue of $38.6B vs. consensus $37.9B. Adj. EPS was $1.29, in line with consensus $1.29. Analyst Mohan Naidu believes that the margin outlook and lack of clarity on organic growth in... More

Leerink Partners Would Buy CVS Health (CVS) on Current Weakness

Leerink Partners reiterated an Outperform rating and $125.00 price target on CVS Health (NYSE: CVS) following the company's 3Q earnings and conference call. Management highlighted that the core business continues to grow at a healthy rate. While 2016E EPS guidance is below consensus expectations, management reiterated that their longterm adjusted EPS growth... More

Growth Drivers Set For LinkedIn's (LNKD) 2016; SunTrust Robinson Humphrey Raises Price Target to $280

SunTrust Robinson Humphrey reiterated a Buy rating on LinkedIn (NYSE: LNKD), and raised the price target to $280.00 (from $275.00), following the company's 3Q earnings results. LinkedIn has multiple drivers that are building momentum for growth in 2016, including; Lynda product improvements, Mobile growth, Sales force... More

Evercore ISI Raises Price target on LinkedIn (LNKD) to $235 Following 3Q

Evercore ISI reiterated a Hold rating on LinkedIn (NYSE: LNKD), and raised the price target to $235.00 (from $211.00), following the company's 3Q earnings results. After stripping out the impact of its Lynda acquisition, billings increased 22%, which compares to +30% growth in reported revenues.

Analyst Ken... More

LinkedIn (LNKD) Reports Upside to 3Q; Needham & Company Reiterates Buy

Needham & Company reiterated a Buy rating on LinkedIn (NYSE: LNKD), and raised the price target to $300.00 (from $260.00), following the company's 3Q earnings results. Total revenue for 3Q15 was $780M, above expectations of $756M. Adjusted EBITDA of $208M was also well above expectations of $152M.... More

NXP Semiconductors (NXPI) Hit by Late 3Q Demand Weakness; Susquehanna Cuts Price Target to $100

Susquehanna maintained a Positive rating on NXP Semiconductors NV (NASDAQ: NXPI), and cut the price target to $100.00 (from $128.00), following the company's 3Q Results. NXPI reported revenue of $1.522 bln, in-line with the lower end of guidance ($1.52 bln-$1.575 bln), but below consensus of $1.552 bln. EPS of $1.57 was well ahead of consensus of $1.50.

Analyst Chris Caso... More

Decline in Secure Interfaces and Power Business Hits NXP Semiconductors' (NXPI) Revenue; Needham & Company Cuts Price Target to $100

Needham & Company maintained a Strong Buy rating on NXP Semiconductors NV (NASDAQ: NXPI), and cut the price target to $100.00 (from $140.00), following the company's 3Q15 earnings report. Revenue of $1.52Bn was slightly below our in-line $1.55Bn estimate, largely due to a decline in the Secure Interfaces and... More

NXP Semiconductors (NXPI) Guides 4Q Down vs. Flat Consensus; Mizuho Securities Reiterates Buy

Mizuho Securities reiterated a Buy rating and $120.00 price target on NXP Semiconductors NV (NASDAQ: NXPI) following the company's 3Q15 earnings results. NXPI reported SepQ earnings that were inline with consensus, but guided DecQ down 15% q/q versus a flat consensus. The down... More

Poor New Product Sales Negatively Effect GoPro's (GPRO) 3Q Revenue; Northland Capital Markets Cuts Price Target to $39

Northland Capital Markets maintained an Outperform rating on GoPro (NASDAQ: GPRO), and cut the price target to $39.00 (from $80.00), following the company's 3Q earnings results. GPRO reported non-GAAP earnings of $0.25, $0.04 below guidance of $0.29-$0.32. Revenue was negatively impacted by weak sales of GPROs new... More

Oppenheimer Remains Sidelined Following a Rough 3Q for GoPro (GPRO)

Oppenheimer maintained a Perform rating on GoPro (NASDAQ: GPRO) following the company's 3Q earnings results and guidance. GPRO guided 4Q sales at $500-550M vs. consensus of $675M, and EPS at $0.35-0.45. GPRO also announced a $300M share repurchase program and more aggressive marketing... More

Allergan (AGN) Affirms Talks with Pfizer (PFE)

Allergan (NYSE: AGN) confirmed that it has been approached by Pfizer Inc. and is in preliminary friendly discussions regarding a potential business combination transaction. Allergan stated that no agreement has been reached and there can be no certainty that these discussions... More